What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?

Group 1 - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is recognized as a high-potential biotech stock with a Buy rating reiterated by HC Wainwright and a price target of $35 [1] - Bank of America Securities also reiterated a Buy rating on Catalyst Pharmaceuticals, setting a price target of $34.00, with a consensus rating of Strong Buy and a median price target of $20.71, indicating a potential upside of 64.17% from current levels [2] - The company is a commercial-stage biopharmaceutical firm focused on developing, in-licensing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases [3]